
Amgen Inc. (NASDAQ: AMGN) stock is down about 1.4% in after-hours trading despite beating estimates on the top and bottom lines in its fourth quarter 2024 earnings report. Investors appear to be selling the news on the company’s latest obesity drug, AMG-513, which was placed on a clinical hold by the FDA. The drug entered Phase 1 trials late in 2024.
As for the report itself, Amgen reported earnings per share (EPS) of $5.31 on revenue of $9.09 billion. Both numbers beat analysts’ estimates for an EPS of $5.08 on revenue of $8.88 billion.